



## **BIOIMPACT LICENSES EPISIL® FOR AUSTRALIA AND NEW ZEALAND FROM CAMURUS AB**

BTC health Limited (ASX:BTC) announced today that its wholly owned subsidiary BioImpact Pty Ltd has entered into a license and supply agreement with Camurus AB of Sweden. The agreement, which is effective immediately, grants BioImpact the exclusive rights to distribute episil® oral liquid in Australia and New Zealand. BioImpact will submit a marketing application in Australia and New Zealand in early 2019 and is planning to launch the product in Australia in 1H2019.

episil® is indicated for the relief of oral pain caused by inflammatory conditions of the mouth such as oral mucositis and stomatitis. It is a lipid-based liquid delivered in a convenient multi-dose pump which forms a mucoadhesive barrier film providing rapid and long last relief of oral pain. episil® is registered as a medical device in Europe (CE mark–class 1), the US (510K) and Japan. It has been launched in 12 countries with additional market approvals pending.

Oral mucositis is a frequent and unpleasant side effect of radiation and chemotherapy. The majority of cancer patients undergoing chemo and radiation therapy will experience at least some degree of oral mucositis. The condition causes redness, mouth sores and ulcers that can be painful, making it difficult to eat, drink and speak. Oral mucositis may lead to nutritional deficiencies or hospitalization as a result of an inability to eat, an increased risk of infection and in some cases may result in interruption or delay of the cancer treatment.

BTC health's Chairman Dr. Richard Treagus commented; "Consistent with our strategy of commercializing novel medical products we are delighted to be partnering with Camurus and we look forward to making make episil® oral liquid available through cancer treatment centres in Australia and New Zealand. We believe episil® oral liquid will make a meaningful difference to the quality of life of cancer patients undergoing chemo or radiotherapy."

### **For more information please contact:**

Dr. Richard Treagus,  
Executive Chairman  
[rtreagus@btchealth.com](mailto:rtreagus@btchealth.com)  
+61 417 520 509

### **About episil®**

**episil® oral liquid** is a medical device for the treatment of inflammatory and painful conditions in the oral cavity, currently being marketed in Europe, Japan, the US and other territories. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces caused by, for example, oral mucositis, a common and serious side effect of cancer treatment. When in contact with the buccal membrane, episil® transforms into a thin protective layer of gel, offering effective pain relief for up to 8 hours. episil® oral liquid is based on Camurus' FluidCrystal® topical bioadhesive technology. For more information, see [www.episil.net](http://www.episil.net).

## About Camurus AB

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).

## Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.